The mixed quarter, revenue miss with EPS beat, may lead to modest near-term volatility. Key catalysts to watch are the FDA decisions on ralinepag (PAH) and Nebulized Tyvaso (IPF) NDAs, expected by mid-2027. Monitor competitive dynamics in inhaled prostacyclins and Tyvaso DPI's ability to offset Nebulized Tyvaso erosion.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 5 $519.01entry
- T+1 · 3mo ago +2.68%α +2.84% · $532.94
- T+5 · 3mo ago −1.40%α −1.76% · $511.72
- T+20 · 3mo ago −5.20%α −4.60% · $492.02
- T+60 · 19d ago +14.09%α +13.89% · $592.12
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
United Therapeutics reported Q2 2026 revenue of $783.3M, down 2% YoY and below the $804.6M consensus, while diluted EPS of $7.27 beat the $6.86 estimate by 5.9%. The revenue miss was driven by a 4% decline in total Tyvaso sales as Nebulized Tyvaso dropped 18% YoY, partially offset by Tyvaso DPI growth. Net income rose 8% YoY to $333.0M, benefiting from a lower effective tax rate (11% vs 24%) and the absence of a prior-year $21.7M PPE impairment. The company highlighted recent NDA submissions for ralinepag (PAH) and Nebulized Tyvaso (IPF) as key pipeline catalysts, but the top-line decline and competitive headwinds in the inhaled prostacyclin class temper the outlook.
Key Financial Metrics
Key Facts
- Revenue decreased 2% YoY to $783.3M, missing consensus of $804.6M.
- Diluted EPS of $7.27 beat consensus of $6.86 by 5.9%.
- Total Tyvaso revenue fell 4% YoY to $452.6M; Nebulized Tyvaso declined 18% to $126.0M.
- Tyvaso DPI revenue grew 4% YoY to $326.6M, with record patient starts and referrals.
- Net income increased 8% YoY to $333.0M, aided by a lower effective tax rate of 11% vs 24%.
- Company submitted NDAs for ralinepag tablets (PAH) and Nebulized Tyvaso (IPF), with potential approvals expected in 2027.
- Share repurchases totaled 2.76M shares under $1.5B ASR agreements; $500M remains authorized through March 2027.
- Cash and investments stood at $3.80B as of June 30, 2026.
Financial Impact
Revenue miss of ~$21M vs consensus; EPS beat of $0.41 per share.
Risk Factors
- Continued competitive pressure on Nebulized Tyvaso and Remodulin from newer therapies.
- Regulatory and clinical risks for ralinepag and Tyvaso DPI in IPF/PPF.
- Potential dilution from share-based compensation and future capital needs for organ manufacturing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001082554-26-000028 |
| Document: uthr-20260805.htm | 0001082554-26-000028 |
| Document: 0001082554-26-000028-index-headers.html | 0001082554-26-000028 |
| Document: 0001082554-26-000028-index.html | 0001082554-26-000028 |
| Document: 0001082554-26-000028.txt | 0001082554-26-000028 |
| 8-K Data (Synthetic) | 0001082554-26-000028 |
Track record
123 reports on UTHR
4 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +10.30% at T+20 after the Oct 14, 2026 report. 5 of 9 went positive at some point.
Filters
- Nov 16, 2026today Insider Cluster Neutral 3/10 Entry price pending
- Nov 13, 20263d ago Insider Cluster Bearish 4/10 Entry $597.50 Now $587.88 +1.61% settles Nov 23
- Nov 12, 20264d ago Insider Cluster Neutral 2/10 Entry $591.17 Now $587.88 −0.56% settles Nov 20
- Nov 10, 20266d ago Insider Cluster Neutral 2/10 Entry $595.66 Now $587.88 −1.31% settles Nov 18
- Nov 9, 20267d ago Insider Cluster Neutral 2/10 Entry $588.61 Now $587.88 −0.12% settles Nov 17
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $588.61 Now $587.88 −0.12% settles Nov 17
- Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $582.46 to $587.88 Now $587.88 +0.93% ▲ +0.93% +2.62% vs SPY
- Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
- Nov 4, 202612d ago SC 13G/A Neutral 2/10 Entry $565.72 to $593.31 Now $587.88 +3.92% ▲ +4.88% +1.59% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers